DNA RNA and Cells

08 Mar 2010 Isis Earns $6 Million Milestone Payment From Bristol-Myers Squibb for BMS-PCSK9Rx
05 Mar 2010 ISIS Initiates Phase 1 Clinical Trial of ISIS-SOD1Rx in Patients With ALS
05 Mar 2010 MOLOGEN AG receives approval for clinical study with cancer drug MGN1703
04 Mar 2010 Argos Therapeutics Publishes Positive Immune Response, Safety and Manufacturing Data for its Arcelis HIV Program in Clinical Immunology
03 Mar 2010 New Research Reveals Mechanism By Which TNFerade(TM) Suppresses Metastases
03 Mar 2010 Second Dose of Gene Therapy for Inherited Blindness Proves Safe in Animal Studies
02 Mar 2010 Pluristem Therapeutics Receives DSMB Approval to Advance to Final Dose Level With PLX-PAD
01 Mar 2010 Quark Announces Dosing of the First Patient in Phase I Clinical Trial of its Ocular Neuroprotective Agent, QPI-1007
25 Feb 2010 The European Medicines Agency is in Overall Agreement with OncoGenex Pharmaceuticals' Development Plan for OGX-011 in Patients with Metastatic Castrate-Resistant Prostate Cancer
25 Feb 2010 Regulus Therapeutics and GlaxoSmithKline Establish New Collaboration to Develop and Commercialize microRNA Therapeutics Targeting miR-122
24 Feb 2010 Aastrom Reports Interim Results From Critical Limb Ischemia Trial
24 Feb 2010 New Study Demonstrates Effectiveness of Prochymal as a Rescue Therapy for Pediatric Patients with Severe Graft vs. Host Disease
23 Feb 2010 Idera Pharmaceuticals Presents Mechanism of Action Data on IMO-3100, a Novel Toll-like Receptor Antagonist for Autoimmune Diseases, at Keystone Symposium
22 Feb 2010 Histostem Participates in Clinical Trials Demonstrating the Effective Use of Its Proprietary Stem Cells in the Treatment of Cirrhosis of the Liver
22 Feb 2010 Alnylam Initiates Phase IIb Clinical Trial of ALN-RSV01 in Adult Lung Transplant Patients Infected with Respiratory Syncytial Virus (RSV) Infection
18 Feb 2010 Dynavax and GlaxoSmithKline Select Clinical Candidate in the Endosomal TLR Inhibitor Program
16 Feb 2010 Athersys Announces Completion of Patient Enrollment in Phase I Study of Multistem(R) in Acute Myocardial Infarction
16 Feb 2010 Oncolytics Biotech(R) Inc. Receives Approval from the U.K. MHRA to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
14 Feb 2010 Idera Pharmaceuticals Presents Preclinical Hyperlipidemia Data on a Toll-like Receptor Antagonist at Keystone Symposium
10 Feb 2010 Data Monitoring Committee Recommends Continuation of Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma
10 Feb 2010 ReNeuron receives final regulatory approval to commence landmark stroke clinical trial in UK
10 Feb 2010 StemCells, Inc. Announces First Human Neural Stem Cell Transplant in Landmark Myelination Disorder Trial
10 Feb 2010 Mipomersen Phase 3 Study in Patients with Heterozygous Familial Hypercholesterolemia Meets Primary Endpoint
04 Feb 2010 Bioheart Launches First US FDA Approved Clinical Trial that Tests Gene-Modified Stem Cell Therapy in Patients with Congestive Heart Failure
04 Feb 2010 AVI BioPharma GLP Safety Pharmacology and Genotoxicity Evaluations of AVI-4658 for Duchenne Muscular Dystrophy Published in the International Journal of Toxicology

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top